Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with Emphysema

New England Journal of Medicine

Volumn 316, Issue 17, 1987, Pages 1055-1062

  Wewers, Mark D ^a   Casolaro, M Anthony ^a   Sellers, Stephanie E ^a   Swayze, Sonia C ^a   McPhaul, Kathleen M ^a   Wittes, Janet T ^a   Crystal, Ronald G ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOSOMAL RECESSIVE DISORDER; AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERANCE; EMPHYSEMA; HEREDITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; PRIORITY JOURNAL; RESPIRATORY SYSTEM; THERAPY;

EID: 0023148995     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198704233161704     Document Type: Article

References (62)

1. Thurlbeck WM, Henderson JA, Fraser RG, Bates DV. Chronic obstructive lung disease: a comparison between clinical, roentgenologic. functional and morphologic criteria in chronic bronchitis, emphysema, asthma and bronchiectasis. Medicine (Baltimore) 1970; 49: 81–145.
2. Snider GL, Kleinerman J. Thurlbeck WM, Bengali ZH. The definition of emphysema: report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis 1985; 132:. 182–5.
3. Laurell C-B, Eriksson S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132–40.
4. Eriksson S. Pulmonary emphysema and alpha1-antitrypsin deficiency. Acta Med Scand 1964; 175: 197–205.
5. Gadek JE, Crystal RG. α1-Antitrypsin deficiency. In: Stanbury JB. Wyngaarden JB, Fredrickson DS. Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill. 1983: 1450–67.
6. Morse JO. Alpha1-antitrypsin deficiency. N Engl J Med 1978; 299: 1045–8, 1099–105.
7. Hutchison DCS. Alpha-1-antitrypsin deficiency and pulmonary emphysema: the role of proteolytic enzymes and their inhibitors. Br J Dis Chest 1973; 67: 171–96.
8. Kueppers F, Black LF. α1-Antitrypsin and its deficiency. Am Rev Respir Dis 1974; 110: 176–94.
9. Idell S, Cohen AB. Alpha-1-antitrypsin deficiency. Clin Chest Med 1983; 4: 359–75.
10. Carrell RW, Owen MC. α1-Antitrypsin: structure, variation, and disease. Essays Biochem 1979; 4: 83–119.
11. National Center for Health Statistics. Ten year review and five year plan. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1983:3.
12. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204: 345–51.
13. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and α1-antitrypsin deficiency. Lancet 1985; 1: 152–4.
14. Tobin MJ, Cook PJL, Hutchison DCS. Alpha1antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. Br J Dis Chest 1983; 77: 14–27.
15. Gadek JE, Fells GA. Zimmerman RL, Rennard SI. Crystal RG.Antielastases of the human alveolar structures: implications for the protease-antiprotease theory of emphysema. J Clin Invest 1981; 68: 889–98.
16. Wewers MD. Casolaro MA, Crystal RG. Comparison of alpha1-antitrypsin levels and anti-neutrophil elastase capacity of blood and lung in a patient with the alpha1-antitrypsin phenotype null-null before and during alpha1-antitrypsin augmentation therapy. Am Rev Respir Dis 1987; 135: 539–43.
17. Janoff A, White R, Carp H, Harel S, Dearing R, Lee D. Lung injury induced by leukocytic proteases. Am J Pathol 1979; 97: 111–36.
18. Janoff A. Elastases and emphysema: current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 1985; 132: 417–33.
19. Carrell RW, Jeppsson J-O, Laurell C-B, et al. Structure and variation of human α1-antitrypsin. Nature 1982; 298: 329–34.
20. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655–709.
21. Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidized α-1-proteinase inhibitor and α-1 -antichymotrypsin. J Biol Chem 1980; 255: 3931–4.
22. Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68: 1158–65.
23. Becker VW, Rapp W, Schwich HG, Storiko K. Methoden zur quantitativen Bestimmung von Plasmaproteinen durch Immunprazipitation. J Clin Chem Clin Biochem 1968; 6: 113–22.
24. Jeppsson J-O, Laurell C-B, Fagerhol M. Properties of isolated human arantitrypsins of Pi types M, S and Z. Eur J Biochem 1978; 83: 143–53.
25. Pannell R, Johnson D, Travis J. Isolation and properties of human plasma α-1-proteinase inhibitor. Biochemistry 1974; 13: 5439–45.
26. Straus SD, Fells GA, Wewers MD, et al. Evaluation of recombinant DNA-directed E.coli produced α1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of α1-antitrypsin deficiency. Biochem Biophys Res Commun 1985; 130: 1177–84.
27. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532–8.
28. Castillo MJ, Nakajima K, Zimmerman M, Powers JC. Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases. Anal Biochem 1979; 99: 53–64.
29. Meyer J-F, Bieth J, Metais P. On the inhibition of elastase by serum: some distinguishing properties of α1-antitrypsin and α2-macroglobulin. Clin Chim Acta 1975; 62: 43–53.
30. Constans J, Viau M, Gouaillard C. PiM4: an additional PiM subtype. Hum Genet 1980; 55: 119–21.
31. Coan MH, Brockway WJ, Eguizabal H, Krieg T, Fournel M. Preparation and properties of alpha1proteinase inhibitor concentrate from human plasma. Vox Sang 1985; 48: 333–42.
32. Morse JO, Lebowitz MD, Knudson RJ, Burrows B. A community study of the relation of alpha1-antitrypsin levels to obstructive lung diseases. N Engl J Med 1975; 292: 278–81.
33. Shigeoka JW, Hall WJ, Hyde RW, et al. The prevalence of alpha1-antitrypsin heterozygotes (Pi MZ) in patients with obstructive pulmonary disease. Am Rev Respir Dis 1976; 114: 1077–84.
34. Morse JO, Lebowitz MD. Knudson RJ, Burrows B. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. N Engl J Med 1977; 296: 1190–4.
35. Bruce RM, Cohen BH, Diamond EL, et al. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects. Am Rev Respir Dis 1985; 130: 386–90.
36. Hutchison DCS, Tobin MJ, Cook PJL. Alpha1antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ: a survey by the British Thoracic Association. Br J Dis Chest 1983; 77: 28–34.
37. Larsson C, Dirksen H, Sundström G, Eriksson S. Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (Pi Z) reduced levels of α1-antitrypsin. Scand J Respir Dis 1976; 57: 267–80.
38. Strumpf U, Feld MK, Cornelius MJ, Keogh BA, Crystal RG. Safety of fiberoptic bronchoalveolar lavage in evaluation of interstitial lung disease. Chest 1981; 80: 268–71.
39. Ouchterlony O, ed. Diffusion-in-gel methods for immunological analysis. Ann Arbor, Mich.: Ann Arbor Science Publishers, 1968:21–31.
40. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG. Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 1980; 104: 205–14.
41. Berman M, Weiss MF, Shahn E. Some formal approaches to the analysis of kinetic data in terms of linear compartmental systems. Biophys J 1962; 2: 289–316.
42. Gross P, Pfitzer EA, Tolker E, Babyak MA, Kaschak M. Experimental emphysema. Arch Environ Health 1965; 11: 50–8.
43. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 1977; 116: 469–75.
44. Janoff A, Sloan B, Weinbaum G, et al. Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. Am Rev Respir Dis 1977; 115: 461–78.
45. Karlinsky JB, Snider GL. Animal models of emphysema. Am Rev Respir Dis 1978; 117: 1109–33.
46. Gadek JE, Hunninghake GA, Fells GA, Zimmerman RL, Keogh BA, Crystal RG. Evaluation of the protease-an ti protease theory of human destructive lung disease. Bull Eur Physiopathol Respir 1980; 16: Suppl: 27–40.
47. Lieberman J. Elastase, collagenase, emphysema, and alpha1-antitrypsin deficiency. Chest 1976; 70: 62–7.
48. Stone PJ. The elastase-antielastase hypothesis of the pathogenesis of emphysema. Clin Chest Med 1983; 4: 405–12.
49. Stockley RA. Proteolytic enzymes, their inhibitors and lung diseases. Clin Sci 1983; 64: 119–26.
50. Fagerhol MK, Laurel C-B. The polymorphism of “prealbumins” and α1-antitrypsin in human sera. Clin Chim Acta 1967; 16: 199–203.
51. Pierce JA, Eradio B, Dew TA. Antitrypsin phenotypes in St. Louis. JAMA 1975; 231: 609–12.
52. Dykes DD, Miller SA, Polesky HF. Distribution of α1-antitrypsm variants in a US white population. Hum Hered 1984; 34: 308–10.
53. Fagerhol MK, Cox DW. The Pi polymorphism: genetic, biochemical, and clinical aspects of human α1-antitrypsin. Adv Hum Genet 1981; 11: 1–62.
54. Sveger T, Mazodier P. Alpha1-antitrypsin screening of 18-year-old men. Thorax 1979; 34: 397–400.
55. Sveger T. Liver disease in aipha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294: 1316–21.
56. Gellis SS, Neefe JR, Stokes J Jr, Strong LE, Janeway CA, Scatchard G. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 1948; 27: 239–44.
57. Murray R, Diefenbach WCL. Effect of heat on the agent of homologous serum hepatitis. Proc Soc Exp Biol Med 1953; 84: 230–1.
58. Levy JA, Mitra G, Mozen MM. Recovery and inactivation of infectious retroviruses from factor VIII concentrates. Lancet 1984; 2: 722–3.
59. Spire B, Dormont D, Barré-Sinoussi F, Montagnier L, Chermann JC. Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet 1985; 1: 188–9.
60. McDougal JS, Martin LS, Cort SP, Mozen M, Heldebrant CM, Evatt BL. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest 1985; 76: 875–7.
61. Blood policy and technology. Washington, D.C.: Office of Technology Assessment, January 1985. (OTA-H-260.)
62. Burrows B. A clinical trial of efficacy of antiproteolytic therapy: can it be done? Am Rev Respir Dis 1983; 127: S42–S43.